Results 161 to 170 of about 7,464 (222)
Some of the next articles are maybe not open access.
Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.
AIDS reviews, 2016Rezolsta® (darunavir/cobicistat) is the first boosted protease inhibitor in a fixed-dose combination to be approved for the treatment of HIV infection. It contains darunavir, a protease inhibitor with a well-known safety and efficacy profile, and the new pharmacokinetic enhancer cobicistat.
Adrián, Curran +2 more
openaire +1 more source
Cobicistat, a pharmacoenhancer for HIV treatments
Drugs of Today, 2013Cobicistat is a novel cytochrome P450 3A4 (CYP3A4) inhibitor in advanced clinical evaluation for use as a pharmacoenhancer of antiretroviral drugs. It lacks significant anti-HIV activity and is more selective than ritonavir in its enzyme inhibition. In addition, its water solubility may lend itself to coformulation with other drugs.
openaire +2 more sources
Elvitegravir/cobicistat, mirabegron, and linaclotide
Journal of the American Pharmacists Association, 2012Daniel A, Hussar, Loren N, Martinez
openaire +2 more sources